Skip to main content

Advertisement

Figure 1 | BMC Cancer

Figure 1

From: Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes

Figure 1

Western blot analysis demonstrating specificty of CDC25s antibodies. (a) One μg of CDC25A (lane 1), CDC25B (lane 2) and CDC25C (lane 3) antigens were immunoblotted with CDC25A, CDC25B, CDC25C and phospho-CDC25C (Ser216) antibodies, respectively. (b) Untreated (lane 1) and CIAP treated (lane 2) protein extracts from the vulvar cancer cell line CAL-39 were immunoblotted with CDC25A, CDC25B, CDC25C and phospho-CDC25C (Ser216) antibodies, respectively. (c) One μg of CDC25B antigen untreated (lane 1) and treated (lane 2) with CHK1 immunoblotted with CDC25B and phospho-CDC25C (Ser216) antibodies, respectively. Immunohistochemical staining of CDC25B (d) and phospho-CDC25C (Ser216) (e) on serial sections of vulvar carcinomas.

Back to article page